This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ZFGN Zafgen (ZFGN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About Zafgen Stock (NASDAQ:ZFGN) 30 days 90 days 365 days Advanced Chart Get Zafgen alerts:Sign Up Key Stats Today's Range$3.06▼$3.2250-Day Range$0.99▼$25.0652-Week Range$0.62▼$2.76Volume516,014 shsAverage Volume360,199 shsMarket Capitalization$119.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts. Read More Receive ZFGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zafgen and its competitors with MarketBeat's FREE daily newsletter. Email Address ZFGN Stock News HeadlinesTokyo Steel Manufacturing Co Ltd 5423May 16, 2024 | morningstar.comMGlobal Weight Loss Therapeutics Professional Market 2023 (Exclusive Report) | Future Work Trend by 2030April 9, 2023 | marketwatch.comA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them. | American Alternative (Ad)Zafgen (ZFGN) Stock Skyrockets on Positive Obesity Drug ResultsFebruary 26, 2023 | thestreet.comZafgen (ZFGN) Stock Surges on Positive Obesity Drug TrialJanuary 13, 2023 | thestreet.comFood and drink in a castleNovember 8, 2022 | bbc.co.ukLRMR Larimar Therapeutics, Inc.September 30, 2022 | seekingalpha.comForm 424B5 Larimar Therapeutics, - StreetInsider.comSeptember 14, 2022 | streetinsider.comSee More Headlines ZFGN Stock Analysis - Frequently Asked Questions How were Zafgen's earnings last quarter? Zafgen Inc (NASDAQ:ZFGN) posted its quarterly earnings data on Thursday, March, 5th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.19). What other stocks do shareholders of Zafgen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zafgen investors own include Xtrackers California Municipal Bond ETF (CA), Bristol Myers Squibb (BMY), Endologix (ELGX), Energy Transfer (ET), BlackRock (BLK), TG Therapeutics (TGTX) and SCYNEXIS (SCYX). Company Calendar Last Earnings3/05/2020Today7/05/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ZFGN CIK1374690 Webwww.zafgen.com Phone617-622-4003FaxN/AEmployees38Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-51.34% Return on Assets-34.55% Debt Debt-to-Equity Ratio0.26 Current Ratio6.56 Quick Ratio6.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.35 per share Price / Book2.37Miscellaneous Outstanding Shares37,470,000Free FloatN/AMarket Cap$119.90 million OptionableNot Optionable Beta0.27 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:ZFGN) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zafgen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Zafgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
